Phase II Trial of Velcade (Bortezomib) in Patients With Previously Untreated Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 Oct 2013 Planned end date changed from 1 Sep 2008 to 1 Jul 2014 as reported by ClinicalTrials.gov.